patients able to provide informed consent or who have already given leave of use of their data for research in the retrospective part; waiving of the informed consent may be applied if national regulations allow to do so;
patients who have undergone at least one cycle of immune checkpoint inhibitors before the onset of intestinal symptoms;
patients with at least one colonoscopy showing macroscopical and/or histological colitis after commencement of immune checkpoint inhibitors therapy; for retrospective patients only, a follow-up of at least 12 months, unless death occurred before.
You may not be if
Evidence of colitis/inflammatory bowel disease prior to checkpoint inhibitors administration
Clareo Health | Long-term Follow-up of Checkpoint Inhibitors-induced Ileo-colitis
